You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Astellas ranked 25th on list for its commitment to changing tomorrow for patients and communities NORTHBROOK, Ill., Feb. 10, 2017 – Astellas is committed to changing tomorrow for the patients we...
Astellas Americas Names Catherine Levitt Regional General Counsel for the Americas Appoints Chieko Mori Vice President Corporate Development NORTHBROOK, Ill., Feb. 8, 2017 /PRNewswire/ -- Astellas...
NORTHBROOK, Illinois, Jan. 19, 2017 – Astellas has been named for the second year one of Corporate Knights’ 2017 Global 100 Most Sustainable Corporations in the World, moving up 10 spots in...
- Complete results of Phase 1/2 CHRYSALIS trial of gilteritinib in patients with Relapsed/Refractory AML to be presented during Oral Session on Dec. 5 - NORTHBROOK, Ill., Nov. 17, 2016 /PRNewswire/ --
Follow U.S. news
